Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Compliance FDA

QUOTED. Nov. 21, 2017. Steve Niedelman.

  • Analysis

Executive Summary

Check out what King & Spalding's Steve Niedelman had to say about device-makers being extra careful about what they tell a US FDA investigator.

"[If] the investigator found something bad, don’t point them to other things that are bad. Instead, take your lumps on the one thing that’s bad and don’t open the kimono for everything else that’s going on. Because if you do, that inspection will just grow. What may have started as what was intended as a week inspection, well, FDA could now be in there for six months. You want to avoid that." – Steve Niedelman, lead quality systems and compliance consultant, King & Spalding

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Compliance FDA
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT121787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By